Publication | Closed Access

Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial

Metabolic SyndromeDiabetes ManagementLow DosageHealth SciencesDiabetes EpidemiologyMedicineDiabetesClinical TrialsType 2Clinical PharmacologyPharmacotherapyDiabetes MellitusPharmacologyPathophysiological Insights